News Daily News FDA Approves Triple Therapy Polypill for High Blood Pressure Michael O'Riordan June 10, 2025
News Daily News Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD Michael O'Riordan March 06, 2025
News Daily News ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials Michael O'Riordan February 20, 2025
News Daily News FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy L.A. McKeown November 25, 2024
News Daily News British Medical Groups Express Concern About Inclisiran Rollout Michael O'Riordan December 14, 2021
News Daily News Xience Cleared in Europe for 1-Month DAPT in High-Bleeding-Risk Patients Shelley Wood April 06, 2021
News Daily News Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval Michael O'Riordan March 03, 2021
News Daily News FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention Shelley Wood June 01, 2020
News Daily News Most Secondary Prevention Patients Are Eligible for Multiple Drugs Michael O'Riordan January 03, 2020
News Daily News PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction Michael O'Riordan April 29, 2019
News Daily News Debate Over BMS vs DES in High-Bleeding-Risk Scenarios Gets Fresh Fuel in Meta-analysis Yael L. Maxwell November 05, 2018
News Daily News FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients Todd Neale October 12, 2018